liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Some Synonymous and Nonsynonymous gyrA Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDRsl Assays
Birmingham Heartlands Hospital, England.
Corp Invest Biol, Colombia; University of Pontificia Bolivariana, Colombia.
Research Centre Borstel, Germany; German Centre Infect Research, Germany.
University of Oxford, England.
Show others and affiliations
2017 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 61, no 4, e02169-16Article in journal (Refereed) Published
Abstract [en]

In this study, using the Hain GenoType MTBDRsl assays (versions 1 and 2), we found that some nonsynonymous and synonymous mutations in gyrA in Mycobacterium tuberculosis result in systematic false-resistance results to fluoroquinolones by preventing the binding of wild-type probes. Moreover, such mutations can prevent the binding of mutant probes designed for the identification of specific resistance mutations. Although these mutations are likely rare globally, they occur in approximately 7% of multidrug-resistant tuberculosis strains in some settings.

Place, publisher, year, edition, pages
AMER SOC MICROBIOLOGY , 2017. Vol. 61, no 4, e02169-16
Keyword [en]
Mycobacterium tuberculosis; Hain GenoType MTBDRsl; fluoroquinolones
National Category
Microbiology in the medical area
Identifiers
URN: urn:nbn:se:liu:diva-136869DOI: 10.1128/AAC.02169-16ISI: 000397598800031PubMedID: 28137812OAI: oai:DiVA.org:liu-136869DiVA: diva2:1092104
Note

Funding Agencies|Swedish Heart and Lung Foundation; Marianne and Marcus Wallenberg Foundation; Wellcome Trust [201344/Z/16/Z]; NIHR Oxford Biomedical Research Centre; NIHR Oxford Health Protection Research Unit on Healthcare Associated Infection and Antimicrobial Resistance [HPRU-2012-10041]; Health Innovation Challenge Fund [T5-358, HICF-T5-342, WT098600]; German Center for Infection Research (DZIF); European Union TB-PAN-NET [FP7-223681]; PathoNgenTrace [278864]; UK Department of Health; Pacific Biosciences, Inc.; Illumina, Inc.; Colciencias; Hain Lifescience

Available from: 2017-04-30 Created: 2017-04-30 Last updated: 2017-05-21

Open Access in DiVA

fulltext(579 kB)21 downloads
File information
File name FULLTEXT01.pdfFile size 579 kBChecksum SHA-512
a2242c1bfe14daf26a2f4f43dda66ac95014b6cef41d9c9db2fe1ed64f5a469bfe716eac81c2053cdeb7ede81bba9961272f949036dd1d331a1220d02e62f56a
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Schön, Thomas
By organisation
Division of Microbiology and Molecular MedicineFaculty of Medicine and Health Sciences
In the same journal
Antimicrobial Agents and Chemotherapy
Microbiology in the medical area

Search outside of DiVA

GoogleGoogle Scholar
Total: 21 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 89 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf